微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 62.35% | 25.78% | 13.89% | 49/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 54.75% | -2.3% | -3.46% | 64/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 56.71% | -5.4% | 21.37% | 60/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 46.72% | -24.34% | -5.75% | 82/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 49.57% | -17.46% | -11.54% | 67/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 56.04% | -17.92% | -6.53% | 65/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 59.95% | -14.9% | -2.93% | 52/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 61.76% | -13.43% | 2.84% | 47/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 60.06% | -15.18% | -12.04% | 50/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 68.27% | 0.6% | -3.08% | 37/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 70.44% | 4.69% | -1.26% | 34/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 71.34% | 6.31% | 0.77% | 32/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 70.8% | 6.25% | 4.32% | 35/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 67.87% | -9.01% | 0.86% | 42/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 67.29% | -11.22% | 0.26% | 45/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 67.11% | -12.38% | 0.71% | 47/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 66.64% | -12.66% | -10.66% | 42/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 74.59% | -3.96% | -1.59% | 34/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 75.8% | -3.39% | -1.05% | 25/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 76.6% | -1.8% | 0.4% | 26/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 76.29% | -1.58% | -1.77% | 22/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 77.66% | 7.03% | -1.01% | 25/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 78.45% | 10.79% | 0.58% | 20/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 78% | 11.23% | 0.63% | 19/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 77.51% | 20.56% | 6.82% | 20/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 72.56% | 13.09% | 2.47% | 33/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 70.82% | 11.72% | 0.98% | 26/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 70.13% | 6.64% | 9.07% | 28/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 64.3% | 1.98% | 0.21% | 31/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 64.16% | 1.95% | 1.23% | 44/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 63.39% | -3.04% | -3.61% | 31/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 65.76% | 13.44% | 4.3% | 26/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 63.05% | 5.91% | 0.18% | 34/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 62.94% | 21.46% | -3.72% | 38/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 65.37% | 26.98% | 12.77% | 22/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 57.97% | 20.88% | -2.62% | 30/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 59.53% | 40.34% | 14.88% | 24/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 51.82% | -7.11% | 0.65% | 45/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 51.48% | -2.97% | 7.35% | 29/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 47.96% | -12.4% | 13.06% | 38/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 42.42% | -24.23% | -23.95% | 39/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |